Abstract
The combination of fludarabine, cyclophosphamide and rituximab is regarded as the gold-standard treatment for chronic lymphocytic leukemia in many parts of the world, although rituximab has not yet been licensed for this use. To date, no randomized, controlled trials have been fully published that demonstrate the superiority of this regimen over other treatments. The results of an open-label, phase II trial with long-term follow-up data on 300 patients with chronic lymphocytic leukemia treated with this regimen are discussed here. Although this study reported impressive efficacy, information on modern prognostic markers such as immunoglobulin gene mutational status and chromosomal deletions was absent, and so it is impossible to say whether the most challenging cases, as identified by these markers, were included in the trial. The most important toxicity was prolonged cytopenia, which occurred both at the end of treatment and later after bone-marrow recovery. At least half of patients with chronic lymphocytic leukemia are over 70 years of age and this regimen might be too toxic for such individuals.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dighiero G and Hamblin TJ (2008) Chronic lymphocytic leukemia. Lancet 371: 1017–1029
Catovsky D et al. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 370: 230–239
Hallek M et al. (2008) Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) [abstract]. Blood 112: a125
Milligan DW et al. (2005) Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 105: 397–404
Hamblin AD and Hamblin TJ (2008) The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull 87: 49–62
Tam CS et al. (2008) Long term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112: 975–980
O'Brien S et al. (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19: 1414–1420
Keating M et al. (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92: 1165–1171
Cheson BD et al. (1996) National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87: 4990–4997
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Hamblin, T. Fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia: no country for old men?. Nat Rev Clin Oncol 6, 130–131 (2009). https://doi.org/10.1038/ncponc1318
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1318